Abstract
Background and aims: The primary aim of the present review was to summarize the findings of genetic studies conducted on problem and pathological gambling. Method: Literature searches were conducted using PubMed, Medline and the HuGE Navigator databases using the keywords ‘gambling’ and ‘genetic*’. Results: The literature searches identified 21 empirical studies that had analyzed data from eight independent samples. Empirical research utilizing twin data accounted for eight of the studies, while gene association data were presented in 13 studies (including one genome wide-association study [GWAS] study). Twin studies emphasized the significant role of genetic and individual environmental factors in problem and pathological gambling. Gene association studies primarily reported the involvement of the dopaminergic and serotonergic systems. Discussion: Despite the relatively low number of genetic studies, the data clearly indicated the genetic vulnerability of problem and pathological gambling. Studies to date have mainly investigated and verified the role of factors reported to be important in other types of addiction, and it is suggested that pathological gambling should be included as a subtype of ‘Reward Deficiency Syndrome’ (RDS). It is concluded that future research should attempt to identify possible gambling specific susceptibility factors.
Keywords: Problem/pathological gambling, gambling addiction, behavioral addiction, systematic review, twin studies, genetic association studies, reward deficiency syndrome.
Current Pharmaceutical Design
Title:The Genetics of Problem and Pathological Gambling: A Systematic Review
Volume: 20 Issue: 25
Author(s): Agoston Gyollai, Mark D. Griffiths, Csaba Barta, Andrea Vereczkei, Robert Urban, Bernadette Kun, Gyongyi Kokonyei, Anna Szekely, Maria Sasvari-Szekely, Kenneth Blum and Zsolt Demetrovics
Affiliation:
Keywords: Problem/pathological gambling, gambling addiction, behavioral addiction, systematic review, twin studies, genetic association studies, reward deficiency syndrome.
Abstract: Background and aims: The primary aim of the present review was to summarize the findings of genetic studies conducted on problem and pathological gambling. Method: Literature searches were conducted using PubMed, Medline and the HuGE Navigator databases using the keywords ‘gambling’ and ‘genetic*’. Results: The literature searches identified 21 empirical studies that had analyzed data from eight independent samples. Empirical research utilizing twin data accounted for eight of the studies, while gene association data were presented in 13 studies (including one genome wide-association study [GWAS] study). Twin studies emphasized the significant role of genetic and individual environmental factors in problem and pathological gambling. Gene association studies primarily reported the involvement of the dopaminergic and serotonergic systems. Discussion: Despite the relatively low number of genetic studies, the data clearly indicated the genetic vulnerability of problem and pathological gambling. Studies to date have mainly investigated and verified the role of factors reported to be important in other types of addiction, and it is suggested that pathological gambling should be included as a subtype of ‘Reward Deficiency Syndrome’ (RDS). It is concluded that future research should attempt to identify possible gambling specific susceptibility factors.
Export Options
About this article
Cite this article as:
Gyollai Agoston, Griffiths D. Mark, Barta Csaba, Vereczkei Andrea, Urban Robert, Kun Bernadette, Kokonyei Gyongyi, Szekely Anna, Sasvari-Szekely Maria, Blum Kenneth and Demetrovics Zsolt, The Genetics of Problem and Pathological Gambling: A Systematic Review, Current Pharmaceutical Design 2014; 20 (25) . https://dx.doi.org/10.2174/13816128113199990626
DOI https://dx.doi.org/10.2174/13816128113199990626 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Aging Successfully: The Role of Genetics and Environment in the Era of the Aging-Boom. Potential Therapeutic Implications
Current Pharmaceutical Design Granulomatous Lung Disease. Disease for Pulmomologists: Diagnosis and Treatment
Current Respiratory Medicine Reviews Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors
CNS & Neurological Disorders - Drug Targets Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs Improvements in Normalized Integrative fMRI–MEG Method by Iterative Model Selection and Theoretical Evaluation
Neuroscience and Biomedical Engineering (Discontinued) Quetiapine Modulates Conditioned Anxiety and Alternation Behavior in Alzheimer’s Transgenic Mice
Current Alzheimer Research Gene Patents Related to Common Diseases of the Eye
Recent Patents on DNA & Gene Sequences Platelet-Derived Secreted Amyloid-Precursor Protein-β as a Marker for Diagnosing Alzheimer’s Disease
Current Neurovascular Research Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry MALDI Mass Spectrometry Imaging, from its Origins up to Today: The State of the Art
Combinatorial Chemistry & High Throughput Screening Predicting Monoamine Oxidase Inhibitory Activity Through Ligand-Based Models
Current Topics in Medicinal Chemistry Exploring Potential of Alkaloidal Phytochemicals Targeting Neuroinflammatory Signaling of Alzheimer's Disease
Current Pharmaceutical Design Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Current Neuropharmacology Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry Rediscovering Tocophersolan: A Renaissance for Nano-Based Drug Delivery and Nanotheranostic Applications
Current Drug Targets De-Novo Ligand Design against Mutated Huntington Gene by Ligand-based Pharmacophore Modeling Approach
Current Computer-Aided Drug Design HMGB1-Directed Drug Discovery Targeting Cutaneous Inflammatory Dysregulation
Current Drug Metabolism